![]() |
|
|
Vol. 283, Issue 2, 528-532, 1997
Department of Physiology, The effects of bufalin on the secretion of testosterone and luteinizing
hormone (LH) and the accumulation of testicular adenosine 3
:5
-cyclic
monophosphate (cAMP) were studied. Male rats were injected with
bufalin, human chorionic gonadotropin (hCG), gonadotropin releasing
hormone (GnRH), hCG plus bufalin or GnRH plus bufalin via a jugular catheter. Blood samples were collected at
several intervals subsequent to the challenge. In the in
vitro study, rat testis blocks were incubated with bufalin, hCG
or both for 1 h. The anterior pituitary gland was incubated with
bufalin, GnRH or both for 30 min. The media were analyzed for
testosterone or LH. For studying cAMP accumulation, testicular blocks
were incubated for 1 h with the medium containing
isobutyl-1-methylxanthine. After incubation, tissues were extracted by
ethanol before measuring cAMP concentration. A single intravenous
injection of bufalin decreased the basal and hCG-stimulated levels of
plasma testosterone. Administration of bufalin in vitro
resulted in an inhibition of both basal and hCG-stimulated release of
testosterone. Bufalin diminished cAMP accumulation in rat testes.
However, the basal levels of plasma and medium LH were not altered by
bufalin administration. Likewise, the LH response to GnRH was
diminished by bufalin administration, both in vivo and
in vitro. These results suggest that the inhibition of
testosterone production by bufalin is partly caused by a decrease of
testicular cAMP accumulation and LH response to GnRH in rats.
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
A. W. Hsing, S. Chua Jr, Y.-T. Gao, E. Gentzschein, L. Chang, J. Deng, and F. Z. Stanczyk Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study J Natl Cancer Inst, May 16, 2001; 93(10): 783 - 789. [Abstract] [Full Text] [PDF] |
||||